Åsa Wallin
41 – 50 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Three-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
-
Mark
Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Activities of Daily Living – Outcome During Three Years in Donepezil Treated Alzheimer Patients.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
-
Mark
Activities of daily living - Outcome during two years in galantamine treated Alzheimer patients
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2006
-
Mark
CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(
- Contribution to journal › Article
-
Mark
Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
New regression models for long-term cognitive change in Donepezil treated Alzheimer patients.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
2-års resultat av rivastigmin (Exelon®) behandling vid Alzheimers sjukdom i klinisk vardag.
2006) Läkarstämman 2006(
- Contribution to conference › Poster
- 2005
-
Mark
Analysis of the heterogeneity in treatment response to Donepezil in Alzheimer’s disease conclusions from the Swedish Alzheimer Treatment Study Group.
(
- Contribution to conference › Poster